var data={"title":"Sodium phenylbutyrate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium phenylbutyrate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6968?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phenylbutyrate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium phenylbutyrate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221871\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Buphenyl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27628435\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pheburane</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062225\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ammonium Detoxicant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperammonemia Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445046\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Urea Cycle Disorders, chronic management:</b> Oral: 450 to 600 mg/kg/day in divided doses with feedings 3 to 6 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062218\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phenylbutyrate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Urea Cycle Disorder, chronic management:</b> <b>Note: </b>The use of sodium phenylbutyrate tablets in children weighing &le;20 kg is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &lt;20 kg: Oral: 450 to 600 mg/kg/day in divided doses with meals/feedings 3 to 6 times daily; minimum daily dose: 20 <b>g</b>/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;20 kg and Adolescents: Oral: 9.9 to 13 <b>g</b>/<b>m<sup>2</sup></b>/day in divided doses with meals 3 to 6 times daily; maximum daily dose: 20 <b>g</b>/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Urea cycle disorders:</b> Oral: 9.9 to 13 <b>g</b>/<b>m<sup>2</sup></b>/day, administered in equally divided doses 3 to 6 times daily; safety and efficacy of doses &gt;20 <b>g</b>/day have not been established</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221862\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buphenyl: (250 g) [contains sodium 125 mg/g]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: (250 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Buphenyl: 500 mg [contains sodium 62 mg/tablet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221850\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21987534\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=sodium-phenylbutyrate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phenylbutyrate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Powder products: 1 level teaspoon provides 3 g sodium phenylbutyrate, 1 level tablespoon provides 8.6 g sodium phenylbutyrate. Measurers provided with the product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062228\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer in equally divided doses with meals or feedings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder: May administer via mouth, gastrostomy tube, or nasogastric tube. Measure the dose using the teaspoon or tablespoon provided; one level teaspoon equals 3 g of sodium phenylbutyrate; 1 level tablespoon equals 8.6 g of sodium phenylbutyrate. The powder may be mixed with solid food, liquid food, or water. When mixed with food, the mixture should be used immediately; if mixed with water, the mixture may be stored at room temperature or refrigerated and must be used within 1 week. When mixing with a liquid, shake lightly prior to use; only sodium phenylbutyrate will dissolve, the excipients will not.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221870\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules (Pheburane [Canadian product]): Use prepared 50 mg/mL solutions for tube administration within 7 days; store in the refrigerator and protect from light with aluminum foil.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for oral solution: Use immediately after mixing powder with food, but stable up to 1 week if dissolved in water and stored at room temperature or in refrigerator.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062227\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive therapy in the chronic management of patients with urea cycle disorder involving deficiencies of carbamoylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase; provides an alternative pathway for waste nitrogen excretion (FDA approved in all ages)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221887\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Syncope</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Depression, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Body odor, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Acidosis, alkalosis, amenorrhea, decreased serum total protein, hyperchloremia, hypernatremia, hyperphosphatemia, hyperuricemia, hypoalbuminemia, hypokalemia, hypophosphatemia, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, dysgeusia, gastritis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukocytosis, leukopenia, thrombocythemia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hyperbilirubinemia, increased serum alkaline phosphatase, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal tubular acidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aplastic anemia, bruise, cardiac arrhythmia, constipation, dizziness, drowsiness, edema, fatigue, memory impairment, neuropathy (exacerbation), pancreatitis, peptic ulcer, rectal hemorrhage</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221865\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to sodium phenylbutyrate or any component of the formulation; management of acute hyperammonemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy, breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221854\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid retention: May cause sodium and fluid retention; use with caution, if at all, in patients where fluid accumulation may be poorly tolerated, such as in HF.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperammonemia: Hyperammonemia and hyperammonemic encephalopathy may still occur while on therapy; manage acute hyperammonemia as a medical emergency. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Signs and symptoms of neurotoxicity were observed at plasma concentrations &ge;3.5 mmol/L, including somnolence, fatigue, lightheadedness, headache, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of preexisting neuropathy; signs and symptoms were reversible upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Inborn errors of beta-oxidation: Use with caution in patients with inborn errors of beta-oxidation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; especially in severe renal impairment when sodium restriction is required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Restricted sodium intake: May contain 125 mg sodium per gram of sodium phenylbutyrate; use with caution, if at all, in patients who must maintain a low sodium intake.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sucrose intolerance (Canadian labeling): Some formulations may contain sucrose; take sucrose content into consideration in patients with diabetes mellitus; avoid use in patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase deficiency. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Tablet formulation: The use of sodium phenylbutyrate tablets in children weighing &le;20 kg is not recommended. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use in conjunction with protein restriction diet and in some cases, essential amino acid supplementation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300066\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673907\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12798&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Corticosteroids (Systemic) may increase protein catabolism and plasma ammonia concentrations, thereby increasing the doses of Urea Cycle Disorder Agents needed to maintain these concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Haloperidol: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Haloperidol may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May diminish the therapeutic effect of Urea Cycle Disorder Agents. More specifically, Valproate Products may increase plasma ammonia concentrations and thereby increase the doses of Urea Cycle Disorder Agents needed to maintain concentrations in the target range.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221859\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use during pregnancy is contraindicated in the Canadian labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062224\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood ammonia, serum proteins, and plasma amino acid and glutamine concentrations, serum electrolytes, CBC with differential, hepatic and renal function tests, urinalysis, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment); nutritional parameters (weight, height, head circumference, albumin, prealbumin)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50426829\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Target biochemical markers for control (Berry 2001):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Plasma ammonia: &lt;40 micromol/L; Plasma glutamine &lt;1,000 micromol/L; normal plasma levels of alanine, glycine, lysine, and arginine (except in arginase deficiency), no subnormal concentrations of essential amino acids (eg, leucine, isoleucine, valine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221853\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Sodium phenylbutyrate is a prodrug which is rapidly converted to phenylacetate, followed by conjugation with glutamine to form phenylacetylglutamine; phenylacetylglutamine serves as a substitute for urea as it is clears nitrogenous waste from the body when excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5673910\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 0.2 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic and renal: Phenylbutyrate, a prodrug, is metabolized to phenylacetate followed by conjugation with glutamine to phenylacetylglutamine </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Phenylbutyrate (tablets and powder): 0.76 to 0.77 hours; Phenylacetate (tablets and powder): 1.15 to 1.29 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Phenylbutyrate (tablets and powder): 1 to 1.35 hours; Phenylacetate (tablets and powder): 3.55 to 3.74 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80% to 100%, primarily as phenylacetylglutamine)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12817092\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">A 200 mg/mL oral suspension may be prepared with sodium phenylbutyrate powder, USP; Ora-Plus&reg;; and either Ora-Sweet&reg; or Ora-Sweet&reg; SF. Place 12 g of sodium phenylbutyrate in a glass mortar and reduce to a fine powder. Separately, mix 30 mL Ora-Plus&reg; and 30 mL of either Ora-Sweet&reg; or Ora-Sweet&reg; SF for a total volume of 60 mL. Add 30 mL of the vehicle mixture to the powder and mix to a uniform smooth suspension. Transfer the mixture into a 2 oz amber prescription bottle; rinse mortar with vehicle, and add quantity of vehicle sufficient to make 60 mL. Label &ldquo;shake well&rdquo;. Stable for 90 days at room temperature. <b>Note:</b> Authors recommend administering a masking agent such as chocolate syrup or peanut butter, before and after medication administration, to mask the bitter taste.</p>\n    <div class=\"reference\">Caruthers RL and Johnson CE, &quot;Stability of Extemporaneously Prepared Sodium Phenylbutyrate Oral Suspensions,&quot; <i>Am J Health Syst Pharm</i>, 2007, 64(14):1513-5.<span class=\"pubmed-id\">17617502</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221867\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Buphenyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/teaspoon (250 g): $16,353.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Sodium Phenylbutyrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 g/teaspoon (250 g): $5,611.53</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Buphenyl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (250): $8,178.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Sodium Phenylbutyrate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (250): $6,695.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539930\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ammonaps (AT, CZ, DE, DK, ES, FR, GB, HR, HU, IE, IT, LT, LV, MT, NL, NO, PL, PT, RO, SE, SI, SK);</li>\n      <li>Buphenyl (JP, KR, TW);</li>\n      <li>Pheburane (GB, IE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S46-S55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-pediatric-drug-information/abstract-text/11148549 /pubmed\" target=\"_blank\" id=\"11148549 \">11148549 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berry GT and Steiner RD, &ldquo;Long-Term Management of Patients With Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S56-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-pediatric-drug-information/abstract-text/11148550/pubmed\" target=\"_blank\" id=\"11148550\">11148550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brusilow SW, &ldquo;Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion,&rdquo; <i>Pediatr Res</i>, 1991, 29(2):147-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-pediatric-drug-information/abstract-text/2014149 /pubmed\" target=\"_blank\" id=\"2014149 \">2014149 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buphenyl (sodium phenylbutyrate) [prescribing information]. Deerfield, IL: Horizon Therapeutics, Inc; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maestri NE, Brusilow SW, Clissold DB, et al, &ldquo;Long-Term Treatment of Girls With Ornithine Transcarbamylase Deficiency,&rdquo; <i>N Engl J Med</i>, 1996, 335(12):855-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phenylbutyrate-pediatric-drug-information/abstract-text/8778603/pubmed\" target=\"_blank\" id=\"8778603\">8778603</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12798 Version 84.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221871\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F27628435\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062225\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445046\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062218\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221862\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F221850\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21987534\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062228\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F221870\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062227\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221887\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221865\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221854\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300066\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5673907\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221859\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5673904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062224\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50426829\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221853\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F5673910\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F12817092\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221867\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539930\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12798|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-phenylbutyrate-drug-information\" class=\"drug drug_general\">Sodium phenylbutyrate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-phenylbutyrate-patient-drug-information\" class=\"drug drug_patient\">Sodium phenylbutyrate: Patient drug information</a></li></ul></div></div>","javascript":null}